Nationally Ranked Investors Rights Firm Holzer and Holzer LLC Announces Investigation of KalVista (KALV)

[ACCESSWIRE]

ATLANTA, GA / ACCESSWIRE / October 6, 2022 / Holzer & Holzer, LLC is investigating whether KalVista Pharmaceuticals, Inc. ("KalVista" or the "Company") (NASDAQ:KALV) complied with federal securities laws. On October 4, 2022, the Company announced it had terminated its KOMPLETE phase 2 clinical trial for KVD824 due to the observation of liver enzyme elevations in all trial treatment groups. After this announcement, the Company's stock price dropped.

If you purchased KalVista stock and suffered a loss on that investment, you are encouraged to contact Corey Holzer, Esq. at [email protected]  or Joshua Karr, Esq. at [email protected], call our toll-free number at (888) 508-6832, or visit our website at www.holzerlaw.com/case/kalvista to discuss your legal rights. 

Holzer & Holzer, LLC, a Top 50 securities litigation law firm for 2021, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct.More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content. 

CONTACT: 
Corey Holzer, Esq. 
(888) 508-6832 (toll-free) 
[email protected]

SOURCE: Holzer & Holzer